Literature DB >> 18502337

An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.

Anna M Sawka1, James D Brierley, Richard W Tsang, Lehana Thabane, Lorne Rotstein, Amiram Gafni, Sharon Straus, David P Goldstein.   

Abstract

Radioactive iodine remnant ablation (RRA) is used to destroy residual normal thyroid tissue after complete gross surgical resection of papillary or follicular thyroid cancer. The article updates a prior systematic review of the literature to determine whether RRA decreases the risk of thyroid cancer-related death or recurrence at 10 years after initial surgery, including data from 28 studies. No long-term randomized trials were identified, so the review is limited to observational studies. The incremental benefit of RRA in low risk patients with well-differentiated thyroid cancer after total or near-total thyroidectomy who are receiving thyroid hormone suppressive therapy remains unclear.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502337     DOI: 10.1016/j.ecl.2008.02.007

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  63 in total

1.  Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.

Authors:  Frederik A Verburg; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-17       Impact factor: 9.236

2.  Pediatric thyroid cancers: an Indian perspective.

Authors:  Devendra A Chaukar; Abhishek D Vaidya
Journal:  Indian J Surg Oncol       Date:  2012-02-16

3.  Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer.

Authors:  E Robenshtok; R Michael Tuttle
Journal:  Indian J Surg Oncol       Date:  2011-12-20

4.  Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection.

Authors:  Amanda M Laird; Paul G Gauger; Barbra S Miller; Gerard M Doherty
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

5.  Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?

Authors:  Colleen M Kiernan; Alexander A Parikh; Lee L Parks; Carmen C Solórzano
Journal:  J Am Coll Surg       Date:  2014-12-17       Impact factor: 6.113

Review 6.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 7.  Managing newly diagnosed thyroid cancer.

Authors:  Anna M Sawka; James D Brierley; Shereen Ezzat; David P Goldstein
Journal:  CMAJ       Date:  2013-10-07       Impact factor: 8.262

Review 8.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

9.  One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer.

Authors:  Markus Dietlein; F A Verburg; M Luster; C Reiners; F Pitoia; H Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05       Impact factor: 9.236

10.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.